Paul Kassner
About Paul Kassner
Paul Kassner, Ph.D. at RAPT Therapeutics
Paul Kassner, Ph.D., joined RAPT Therapeutics in 2016, where he currently serves as the Senior Vice President of Quantitative and Computational Biology. He plays a pivotal role in steering innovative research and development efforts at the company. RAPT Therapeutics focuses on the discovery and development of therapeutics in oncology and inflammatory diseases, leveraging Dr. Kassner's expertise in high-throughput platforms for drug discovery and target identification.
Paul Kassner, Ph.D. at Amgen Inc.
Before his tenure at RAPT Therapeutics, Paul Kassner, Ph.D., accumulated significant experience at Amgen Inc. He served as the Director of Research and Head of the Genome Analysis Unit. Over his eleven years at Amgen, he developed and implemented various high-throughput platforms designed for drug discovery and target identification across diverse therapeutic areas. His contributions significantly advanced Amgen's capabilities in biotechnology innovation.
Paul Kassner's Education Background
Paul Kassner, Ph.D., has a comprehensive educational background in genetics and immunology. He earned his B.S. in Genetics and Development from the University of Illinois at Champaign-Urbana. Following his undergraduate studies, he performed graduate research at the Dana-Farber Cancer Institute and went on to earn his Ph.D. in Immunology from Harvard University. Additionally, he completed postdoctoral work in cellular neuroscience at the University of California, San Diego, further enhancing his expertise in biomedical sciences.
Paul Kassner's Career in Research and Leadership
Throughout his career, Paul Kassner, Ph.D., has held several significant scientific and leadership positions in various companies. His roles have spanned from research-centric positions to high-level leadership, where he has been passionate about creating novel technology platforms to enable drug discovery. His diverse experiences in both large organizations like Amgen and several smaller companies have equipped him with a unique perspective on the biotech industry.